Review
Medicine, Research & Experimental
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Summary: Crohn's disease and ulcerative colitis, as chronic autoimmune diseases, are rapidly increasing in incidence in Asia. Monoclonal antibodies (mAbs) have shown promising effects in treating IBD, particularly moderate-to-severe CD and UC, by targeting inflammatory pathways. This review comprehensively summarizes the clinical reports and studies on the use of mAbs in IBD treatment in Asian countries, highlighting the current status and differences with the West.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Gastroenterology & Hepatology
Stefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkus, Maciej Kowalski, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Seul Gi Lee, Byong Duk Ye, Walter Reinisch
Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.
Article
Gastroenterology & Hepatology
Jurij Hanzel, Laura H. Bukkems, Krisztina B. Gecse, Geert R. D'Haens, Ron A. A. Mathot
Summary: The study characterized the pharmacokinetics of subcutaneous CT-P13 through population PK modeling, identifying body weight, presence of anti-drug antibodies, and serum albumin concentration as clinically relevant covariates affecting drug clearance. Simulated drug exposure demonstrated differences between routes of administration in patients of varying body weights.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Gastroenterology & Hepatology
Abhinav Vasudevan, Vivek Tharayil, Laura H. Raffals, David H. Bruining, Michelle Becker, Mohammad Hassan Murad, Edward Loftus
Summary: A systematic review and meta-analysis found an association between serum ustekinumab trough concentrations and treatment response in patients with inflammatory bowel disease.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Oncology
Livia Moreira Genaro, Luis Eduardo Miani Gomes, Ana Paula Menezes de Freitas Franceschini, Hugo Dugolin Ceccato, Rafael Nascimento de Jesus, Amanda Pereira Lima, Cristiane Kibune Nagasako, Joao Jose Fagundes, Maria de Lourdes Setsuko Ayrizono, Raquel Franco Leal
Summary: Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic illnesses characterized by intestinal inflammation. Current treatment focuses on inducing and maintaining remission, with monoclonal antibodies considered an advanced therapy to prevent complications and reduce the need for surgery. However, these antibodies may trigger immune responses, leading to potential immunogenicity and treatment failure.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2021)
Review
Gastroenterology & Hepatology
Xiaoding Shen, Qianyi Wan, Rui Zhao, Yutao Wu, Yong Wang, Yaping Cui, Xiangnan Su, Xiaoting Wu
Summary: The umbrella review of 25 meta-analyses found that patients with inflammatory bowel diseases had a higher risk of adverse health outcomes in various aspects, but the quality of evidence was generally low. More research is needed to draw firmer conclusions.
DIGESTIVE AND LIVER DISEASE
(2021)
Review
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jorgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukas, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atreya
Summary: This study compared the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn's disease or ulcerative colitis. The results showed that infliximab had better efficacy during the induction phase and comparable efficacy during the maintenance phase compared to vedolizumab. In terms of safety, there were no significant differences between the two treatments.
BMC GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, Laure Payen, Marie Laugie, Luc Manlay, Nicolas Mathieu, Bruno Pereira, Mathurin Fumery
Summary: This study assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs). The results showed that switching from intravenous to subcutaneous infliximab was safe and well accepted, with a low risk of relapse in IBD patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Multidisciplinary Sciences
Ruize Liu, Dalin Li, Talin Haritunians, Yunfeng Ruan, Mark J. Daly, Hailiang Huang, Dermot P. B. McGovern
Summary: This study presents a novel molecular-based prediction model that combines genetics, serum biomarkers, and smoking information to assist in the diagnosis of Crohn's disease and ulcerative colitis. The joint model explains approximately 46% of phenotypic variation, with genetics making unique contributions to distinguishing disease subtypes and smoking status potentially not being an effective biomarker.
Review
Pharmacology & Pharmacy
Alix Demaris, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, Charlotte Kloft
Summary: This review aims to analyze the population PK models of infliximab (IFX) in patients with ulcerative colitis (UC) and acute severe UC (ASUC), and assess the impact of disease activity on IFX PK. The results showed that there are still many gaps in the current research, such as a limited number of models specifically developed for UC patients, a lack of studies on severe UC patients, and a lack of evaluation of predictive performance for the models. Therefore, more comprehensive research and adequate reporting and evaluation of the models are needed for clinical application.
Article
Gastroenterology & Hepatology
Miikka Hoyhtya, Katri Korpela, Schahzad Saqib, Sofia Junkkari, Eija Nissila, Anne Nikkonen, Evgenia Dikareva, Anne Salonen, Willem M. de Vos, Kaija-Leena Kolho
Summary: This study aimed to investigate the absolute abundances of gut microbiota in relation to the response to induction therapy with infliximab in pediatric inflammatory bowel disease. The results showed that the treatment responsive group had a higher absolute abundance of Bifidobacteriales and a lower absolute abundance of Actinomycetales compared to the nonresponders. However, the level of inflammation according to fecal calprotectin showed no statistically significant association with the absolute abundances of fecal microbiota. The results on relative abundances differed from the absolute abundances.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Cell & Tissue Engineering
D. Xu, C. Ding, T. Cheng, C. Yang, X. Zhang
Summary: This study investigated whether patients with inflammatory bowel disease (IBD) undergoing joint arthroplasty have a higher incidence of adverse outcomes compared to those without IBD. The findings suggest that IBD is associated with an increased risk of postoperative complications, including overall complications, medical complications, surgical complications, and 90-day readmissions. Patients with IBD also tend to have longer hospital stays and higher costs of care.
BONE & JOINT RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Medea Salzmann, Thea von Graffenried, Franziska Righini-Grunder, Christian Braegger, Johannes Spalinger, Susanne Schibli, Alain Schoepfer, Andreas Nydegger, Valerie Pittet, Christiane Sokollik
Summary: This study investigated adverse events necessitating drug discontinuation in pediatric and adolescent patients with inflammatory bowel disease (IBD). The findings showed that drug-related adverse events were common in these patients, particularly in those receiving immunomodulators and tumor necrosis factor-α antagonists. The use of multiple drugs concurrently also increased the risk of adverse events.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2022)
Article
Gastroenterology & Hepatology
Camilla de Almeida Martins, Matheus Freitas Cardoso de Azevedo, Alexandre Sousa Carlos, Aderson Omar Mourao Cintra Damiao, Carlos Walter Sobrado Jr, Sergio Carlos Nahas, Natalia Sousa Freitas Queiroz
Summary: This study has enhanced our understanding of the predictive factors of treatment response to IFX in a well-characterized Brazilian IBD population. The study found that the duration of IFX therapy and higher albumin levels increased the likelihood of clinical remission, while previous surgery decreased its chance. Prior use of adalimumab and higher C-reactive protein levels reduced the likelihood of endoscopic remission.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Thomas X. Lu, Matthew Dapas, Erika Lin, Trevor Peters, Atsushi Sakuraba
Summary: In this meta-analysis of randomized controlled studies, patients with IBD who took PPIs were less likely to achieve remission while on infliximab therapy. Further investigation into the effect of PPIs on IBD outcomes and therapies is warranted based on our study's results.